The Inflammasome in Myocardial Injury and Cardiac Remodeling

Antioxidants and Redox Signaling

Volumn 22, Issue 13, 2015, Pages 1146-1161

  Toldo, Stefano ^a,b   Mezzaroma, Eleonora ^a,b   Mauro, Adolfo Gabriele ^a,b   Salloum, Fadi ^a   Van Tassell, Benjamin Wallace ^a,b   Abbate, Antonio ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; CANAKINUMAB; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; MICRORNA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR; URATE; CYTOKINE;

CARDIAC REMODELING; ENZYME ACTIVATION; HEART DISEASE; HEART FUNCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MITOCHONDRIAL MEMBRANE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; HEART VENTRICLE REMODELING; METABOLISM;

ANIMALS; CYTOKINES; HUMANS; INFLAMMASOMES; MYOCARDIAL ISCHEMIA; VENTRICULAR REMODELING;

EID: 84933518034     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5989     Document Type: Review

References (165)

1. Abbate A, Biondi-Zoccai GG, and Baldi A. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol 193: 145-153, 2002.
2. Abbate A, Biondi-Zoccai GG, Brugaletta S, Liuzzo G, and Biasucci LM. C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin Vasc Med 3: 375-384, 2003.
3. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW, and VCU-ART Investigators. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 105: 1371-1377.e1, 2010.
4. Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, Seropian I, Mezzaroma E, and Dobrina A. Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS One 6: e27923, 2011.
5. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, Biondi-Zoccai GG, Houser JE, Qureshi IZ, Ownby ED, Gustini E, Biasucci LM, Severino A, Capogrossi MC, Vetrovec GW, Crea F, Baldi A, Kukreja RC, and Dobrina A. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117: 2670-2683, 2008.
6. Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, and Vetrovec GW. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 111: 1394-1400, 2013.
7. Abbate A, Van Tassell BW, Seropian IM, Toldo S, Robati R, Varma A, Salloum FN, Smithson L, and Dinarello CA. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail 12: 319-322, 2010.
8. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, Bea F, Hardt SE, Humpert PM, Bianchi ME, Mairbäurl H, Nawroth PP, Remppis A, Katus HA, and Bierhaus A. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216-3226, 2008.
9. Arslan F, de Kleijn DP, and Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 8: 292-300, 2011.
10. Bagby GC Jr., Dinarello CA, Wallace P, Wagner C, Hefeneider S, andMcCall E. Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells. J Clin Invest 78: 1316-1323, 1986.
11. Bandyopadhyay S, Lane T, Venugopal R, Parthasarathy PT, Cho Y, Galam L, Lockey R, and Kolliputi N. Micro- RNA-133a-1 regulates inflammasome activation through uncoupling protein-2. Biochem Biophys Res Commun 439: 407-412, 2013.
12. Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, and Hornung V. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 189: 4175-4181, 2012.
13. Biasucci LM, CDC, and AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 110: e560-e567, 2004.
14. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, and Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation 94: 874-877, 1996.
15. Biondi-Zoccai GG, Abbate A, Liuzzo G, and Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 41: 1071-1077, 2003.
16. Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jabagi H, Wright JR Jr., Macdonald JA, Lees-Miller JP, Roach D, Semeniuk LM, and Duff HJ. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1b. Exp Physiol 98: 462-473, 2013.
17. Brocheriou V, Hagège AA, Oubenaïssa A, Lambert M, Mallet VO, Duriez M, Wassef M, Kahn A, Menasché P, and Gilgenkrantz H. Cardiac functional improvement by a human Bcl-2 transgene in a mouse model of ischemia/reperfusion injury. J Gene Med 2: 326-333, 2000.
18. Brydges SD, Broderick L, McGeough MD, Pena CA, Mueller JL, and Hoffman HM. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest 123: 4695-4705, 2013.
19. Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, Putnam CD, Boyle DL, Firestein GS, Horner AA, Soroosh P, Watford WT, O'Shea JJ, Kastner DL, and Hoffman HM. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30: 875-887, 2009.
20. Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, and Frangogiannis NG. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 173: 57-67, 2008.
21. Bulau AM, Nold MF, Li S, Nold-Petry CA, Fink M, Mansell A, Schwerd T, Hong J, Rubartelli A, Dinarello CA, and Bufler P. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc Natl Acad Sci U S A 111: 2650-2655, 2014.
22. Canada JM, Van Tassell BW, Christopher S, Oddi C, Abouzaki NA, Gambill ML, Mueller G, Melchior R, Shah KB, Dinarello CA, Abbate A, and Arena R. Clinical predictors of response to anakinra in patients with heart failure. Int J Cardiol 173: 537-539, 2014.
23. Cayrol C and Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 106: 9021-9026, 2009.
24. Chang H, Wang Y, Li G, Zhang L, Zhang GW, Liao YC, Hanawa H, and Zou J. Effect of hydrodynamics-based delivery of IL-18BP fusion gene on rat experimental autoimmune myocarditis. Clin Exp Med 14: 397-408, 2014.
25. Chen GY and Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10: 826-837, 2010.
26. Christia P and Frangogiannis NG. Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest 43: 986-995, 2013.
27. Chung MK, Gulick TS, Rotondo RE, Schreiner GF, and Lange LG. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res 67: 753-763, 1990.
28. De Nardo D and Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol 32: 373-379, 2011.
29. Denes A, Lopez-Castejon G, and Brough D. Caspase-1: is IL-1 just the tip of the ICEberg? Cell Death Dis 3: e338, 2012.
30. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci 28: 465-472, 2007.
31. Dinarello AC. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27: 519-550, 2009.
32. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117: 3720-3732, 2011.
33. Dobaczewski M, Gonzalez-Quesada C, and Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 48: 504-511, 2010.
34. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, and Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464: 1357-1361, 2010.
35. Eming SA, Hammerschmidt M, Krieg T, and Roers A. Interrelation of immunity and tissue repair or regeneration. Semin Cell Dev Biol 20: 517-527, 2009.
36. Follath F. Nonischemic heart failure: epidemiology, pathophysiology, and progression of disease. J Cardiovasc Pharmacol 33: S31-S35, 1999.
37. Frangogiannis NG, Smith CW, and Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31-47, 2002.
38. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 58: 88-111, 2008.
39. Frantz S, Ducharme A, Sawyer D, Rohde LE, Kobzik L, Fukazawa R, Tracey D, Allen H, Lee RT, and Kelly RA. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 35: 685-694, 2003.
40. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, and American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 127: 143-152, 2013.
41. Gringhuis SI, Kaptein TM, Wevers BA, Theelen B, van der Vlist M, Boekhout T, and Geijtenbeek TB. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1b via a noncanonical caspase-8 inflammasome. Nat Immunol 13: 246-254, 2012.
42. Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McInnes IB, Hammerschmidt W, O'Neill LA, and Masters SL. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL- 1b production. J Immunol 189: 3795-3799, 2012.
43. Hartupee J and Mann DL. Positioning of inflammatory biomarkers in the heart failure landscape. J Cardiovasc Transl Res 6: 485-492, 2013.
44. He J, Yang Y, and Peng DQ. Monosodium urate (MSU) crystals increase gout associated coronary heart disease (CHD) risk through the activation of NLRP3 inflammasome. Int J Cardiol 160: 72-73, 2012.
45. He Y, Franchi L, and Núñez G. The protein kinase PKR is critical for LPS-induced iNOS production but dispensable for inflammasome activation in macrophages. Eur J Immunol 43: 1147-1152, 2013.
46. Headrick JP, Ashton KJ, Rose'meyer RB, and Peart JN. Cardiovascular adenosine receptors: expression, actions and interactions. Pharmacol Ther 140: 92-111, 2013.
47. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, and Mellis SJ. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebocontrolled studies. Arthritis Rheum 58: 2443-2452, 2008.
48. Inoue Y, Shirasuna K, Kimura H, Usui F, Kawashima A, Karasawa T, Tago K, Dezaki K, Nishimura S, Sagara J, Noda T, Iwakura Y, Tsutsui H, Taniguchi S, Yanagisawa K, Yada T, Yasuda Y, and Takahashi M. NLRP3 regulates neutrophil functions and contributes to hepatic ischemiareperfusion injury independently of inflammasomes. J Immunol 192: 4342-4351, 2014.
49. Jefferies JL and Towbin JA. Dilated cardiomyopathy. Lancet 375: 752-762, 2010.
50. Jin J, Yu Q, Han C, Hu X, Xu S, Wang Q, Wang J, Li N, and Cao X. LRRFIP2 negatively regulates NLRP3 inflammasome activation in macrophages by promoting flightless-I-mediated caspase-1 inhibition. Nat Commun 4: 2075, 2013.
51. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, and Alnemri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 287: 36617-36622, 2012.
52. Kaczorowski DJ, Nakao A, McCurry KR, and Billiar TR. Toll-like receptors and myocardial ischemia/reperfusion, inflammation, and injury. Curr Cardiol Rev 5: 196-202, 2009.
53. Kalogeropoulos AP, Georgiopoulou VV, and Butler J. From risk factors to structural heart disease: the role of inflammation. Heart Fail Clin 8: 113-123, 2012.
54. Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GD, Jørgensen T, and Danesh J. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 35: 578-589, 2014.
55. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S, and Ikeda U. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123: 594-604, 2011.
56. Kawano A, Tsukimoto M, Mori D, Noguchi T, Harada H, Takenouchi T, Kitani H, and Kojima S. Regulation of P2X7-dependent inflammatory functions by P2X4 receptor in mouse macrophages. Biochem Biophys Res Commun 420: 102-107, 2012.
57. Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, Zhang J, Lee WP, Roose-Girma M, and Dixit VM. Noncanonical inflammasome activation targets caspase-11. Nature 479: 117-121, 2011.
58. Kim JA, Montagnani M, Chandrasekran S, and Quon MJ. Role of lipotoxicity in endothelial dysfunction. Heart Fail Clin 8: 589-607, 2012.
59. Kukreja RC, Yin C, and Salloum FN. MicroRNAs: new players in cardiac injury and protection. Mol Pharmacol 80: 558-564, 2011.
60. Kumar A, Thota V, Dee L, Olson J, Uretz E, and Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 183: 949-958, 1996.
61. Kumar H, Kawai T, and Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388: 621-625, 2009.
62. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN, and Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360: 2416-2425, 2009.
63. Lamkanfi M and Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28: 137-161, 2012.
64. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, and Rose NR. Interleukin 1 or tumor necrosis factor can promote Coxsackie B3-induced myocarditis in resistant B10.A mice. J Exp Med 175: 1123-1129, 1992.
65. Latz E, Xiao TS, and Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 13: 397-411, 2013.
66. Levine B, Kalman J, Mayer L, Fillit HM, and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 223: 236-241, 1990.
67. Liao YH and Cheng X. Autoimmunity in myocardial infarction. Int J Cardiol 112: 21-26, 2006.
68. Libby P, Ridker PM, and Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
69. Libby P and Theroux P. Pathophysiology of coronary artery disease. Circulation 111: 3481-3488, 2005.
70. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32: 2045-2051, 2012.
71. Liu A, Gao X, Zhang Q, and Cui L. Cathepsin B inhibition attenuates cardiac dysfunction and remodeling following myocardial infarction by inhibiting the NLRP3 pathway. Mol Med Rep 8: 361-366, 2013.
72. Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T, Sato Y, Hiraga N, Adachi N, Yoshino T, and Nishibori M. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21: 3904-3916, 2007.
73. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, and Maseri A. The prognostic value of Creactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331: 417-424, 1994.
74. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundbäck P, Valdes-Ferrer SI, Olofsson PS, Kalb T, Roth J, Zou Y, Erlandsson-Harris H, Yang H, Ting JP, Wang H, Andersson U, Antoine DJ, Chavan SS, Hotamisligil GS, and Tracey KJ. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488: 670-674, 2012.
75. Ludlow LE, Johnstone RW, and Clarke CJ. The HIN-200 family: more than interferon-inducible genes? Exp Cell Res 308: 1-17, 2005.
76. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91: 988-998, 2002.
77. Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, Federici M, Van Tassell BW, Zhang S, and Abbate A. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia- reperfusion in the mouse. J Cardiovasc Pharmacol 63: 316-322, 2014.
78. Mariathasan S and Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7: 31-40, 2007.
79. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, and Dixit VM. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232, 2006.
80. Maseri A and Fuster V. Is there a vulnerable plaque? Circulation 107: 2068-2071, 2003.
81. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, Beck PL, Muruve DA, and Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330: 362-366, 2010.
82. Merkle S, Frantz S, Schön MP, Bauersachs J, Buitrago M, Frost RJ, Schmitteckert EM, Lohse MJ, and Engelhardt S. A role for caspase-1 in heart failure. Circ Res 100: 645-653, 2007.
83. Mezzaroma E, Toldo S, and Abbate A. Role of NLRP3 (cryopyrin) in acute myocardial infarction. Cardiovasc Res 99: 225-226, 2013.
84. Mezzaroma E, Toldo S, Cardnell RJ, Van Tassell BW, Mikkelsen RB, Gewirtz DA, and Abbate A. Role of interleukin- 1 in acute radiation-induced cardiomyopathy. Circulation A17799: 126, 2012.
85. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, and Abbate A. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse, Proc Natl Acad Sci U S A 108: 19725-19730, 2011.
86. Mezzaroma E, Toldo S, Van Tassell BW, Marchetti C, Mikkelsen RB, Gewirtz DA, and Abbate A. Preserved Left Ventricular Contractile Reserve After Thoracic Irradiation in the Interleukin-1 Receptor Knock Out Mouse. AHA Scientific Session 2013, Abstract 14774.
87. Nahrendorf M and Swirski FK. Monocyte and macrophage heterogeneity in the heart. Circ Res 112: 1624-1633, 2013.
88. Nakano A, Matsumori A, Kawamoto S, Tahara H, Yamato E, Sasayama S, and Miyazaki JI. Cytokine gene therapy for myocarditis by in vivo electroporation. Hum Gene Ther 12: 1289-1297, 2001.
89. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, Funk CJ, Mason RJ, Kullberg BJ, Rubartelli A, van der Meer JW, and Dinarello CA. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 113: 2324-2335, 2009.
90. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, and Quartier P. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62: 258-267, 2010.
91. Nozaki N, Shishido T, Takeishi Y, and Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 110: 2869-2874, 2004.
92. O'Brien LC, Mezzaroma E, Van Tassell BW, Marchetti C, Carbone S, Abbate A, and Toldo S. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med 20: 221-229, 2014.
93. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, Oyabu J, Murakawa T, Nakayama H, Nishida K, Akira S, Yamamoto A, Komuro I, and Otsu K. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485: 251-255, 2012.
94. Ouyang X, Ghani A, Malik A, Wilder T, Colegio OR, Flavell RA, Cronstein BN, and Mehal WZ. Adenosine is required for sustained inflammasome activation via the A2A receptor and the HIF-1a pathway. Nat Commun 4: 2909, 2013.
95. Owens LM, Fralix TA, Murphy E, Cascio WE, and Gettes LS. Correlation of ischemia-induced extracellular and intracellular ion changes to cell-to-cell electrical uncoupling in isolated blood-perfused rabbit hearts. Experimental Working Group. Circulation 94: 10-13, 1996.
96. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, and Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370-7377, 2004.
97. Park S, Juliana C, Hong S, Datta P, Hwang I, Fernandes- Alnemri T, Yu JW, and Alnemri ES. The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity. J Immunol 191: 4358-4366, 2013.
98. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr., Taubert K, Tracy RP, Vinicor F, and Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511, 2003.
99. Pfeffer JM, Pfeffer MA, Fletcher PJ, and Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 2605:H1406-H1414, 1991.
100. Piccini A, Carta S, Tassi S, Lasiglié D, Fossati G, and Rubartelli A. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL- 1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci U S A 105: 8067-8072, 2008.
101. Pomerantz BJ, Reznikov LL, Harken AH, and Dinarello CA. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci USA 98: 2871-2876, 2001.
102. Pott GB, Chan ED, Dinarello CA, and Shapiro L. Alpha- 1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 85: 886-895, 2009.
103. Proell M, Riedl SJ, Fritz JH, Rojas AM, and Schwarzenbacher R. The Nod-like receptor (NLR) family: a tale of similarities and differences. PLoS One 3: e2119, 2008.
104. Py BF, Kim MS, Vakifahmetoglu-Norberg H, and Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 49: 331-338, 2013.
105. Rajamäki K, Lappalainen J, Oörni K, Välimäki E, Matikainen S, Kovanen PT, and Eklund KK. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 5: e11765, 2010.
106. Rajamäki K, Nordström T, Nurmi K, Åkerman KE, Kovanen PT, Ö örni K, and Eklund KK. Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J Biol Chem 288: 13410-13419, 2013.
107. Rao RM, Yang L, Garcia-Cardena G, and Luscinskas FW. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 101: 234-247, 2007.
108. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, Hornung V, Vogel SN, Szomolanyi-Tsuda E, and Fitzgerald KA. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 11: 395-402, 2010.
109. Rathinam VA, Vanaja SK, and Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol 13: 333-342, 2012.
110. Riad A, Bien S, Gratz M, Escher F, Westermann D, Heimesaat MM, Bereswill S, Krieg T, Felix SB, Schultheiss HP, Kroemer HK, and Tschöpe C. Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. Eur J Heart Fail 10: 233-243, 2008.
111. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, and Thuren T. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126: 2739-2748, 2012.
112. Rock KL, Latz E, Ontiveros F, and Kono H. The sterile inflammatory response. Annu Rev Immunol 28: 321-342, 2010.
113. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126, 1999.
114. Salloum FN, Chau V, Varma A, Hoke NN, Toldo S, Biondi-Zoccai GG, Crea F, Vetrovec GW, and Abbate A. Anakinra in experimental acute myocardial infarction - does dosage or duration of treatment matter? Cardiovasc Drugs Ther 23: 129-135, 2009.
115. Salloum FN, Yin C, and Kukreja RC. Role of microRNAs in cardiac preconditioning. J Cardiovasc Pharmacol 56: 581-588, 2010.
116. Sandanger Ø, Ranheim T, Vinge LE, Bliksøen M, Alfsnes K, Finsen AV, Dahl CP, Askevold ET, Florholmen G, Christensen G, Fitzgerald KA, Lien E, Valen G, Espevik T, Aukrust P, and Yndestad A. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res 99: 164-174, 2013.
117. Satoh M, Tabuchi T, Itoh T, and Nakamura M. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin. Clin Sci (Lond) 126: 233-241, 2014.
118. Satoh T, Kambe N, and Matsue H. NLRP3 activation induces ASC-dependent programmed necrotic cell death, which leads to neutrophilic inflammation. Cell Death Dis 4: e644, 2013.
119. Sauter KA, Wood LJ, Wong J, Iordanov M, and Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1b through activation of the NLRP3 inflammasome. Cancer Biol Ther 11: 1008-1016, 2011.
120. Saxena A, Chen W, Su Y, Rai V, Uche OU, Li N, and Frangogiannis NG. IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium. J Immunol 191: 4838-4848, 2013.
121. Seropian IM, Toldo S, Van Tassell BW, and Abbate A. Anti-inflammatory strategies for ventricular remodeling following st-segment elevation acute myocardial infarction. J Am Coll Cardiol 63: 1593-1603, 2013.
122. Seta Y, Kanda T, Tanaka T, Arai M, Sekiguchi K, Yokoyama T, Kurimoto M, Tamura J, and Kurabayashi M. Interleukin 18 in acute myocardial infarction. Heart 84: 668, 2000.
123. Seth RB, Sun L, Ea CK, and Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122: 669-682, 2005.
124. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DT, Stuart LM, Latz E, Fitzgerald KA, and Moore KJ. CD36 coordinates NLRP3 inflammasome activation by facilitating the intracellular nucleation from soluble to particulate ligands in sterile inflammation, Nat Immunol 14: 812-820, 2013.
125. Shigeoka AA, Mueller JL, Kambo A, Mathison JC, King AJ, Hall WF, Correia Jda S, Ulevitch RJ, Hoffman HM, and McKay DB. An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. J Immunol 185: 6277-6285, 2010.
126. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, Ramanujan VK, Wolf AJ, Vergnes L, Ojcius DM, Rentsendorj A, Vargas M, Guerrero C, Wang Y, Fitzgerald KA, Underhill DM, Town T, and Arditi M. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36: 401-414, 2012.
127. Sonnino C, Toldo S, Mezzaroma E, and Abbate A. The inflammasome: a new villain in heart disease. Inflammasome 2014. DOI: 10.2478/infl-2014-0003.
128. Strowig T, Henao-Mejia J, Elinav E, and Flavell R. Inflammasomes in health and disease. Nature 481: 278-286, 2012.
129. Stutz A, Golenbock DT, and Latz E. Inflammasomes: too big to miss. J Clin Invest 119: 3502-3511, 2009.
130. Stutz A, Horvath GL, Monks BG, and Latz E. ASC speck formation as a readout for inflammasome activation. Methods Mol Biol 1040: 91-101, 2013.
131. Subramanian N, Natarajan K, Clatworthy MR, Wang Z, and Germain RN. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell 153: 348-361, 2013.
132. Takahashi M. NLRP3 Inflammasome as a novel player in myocardial infarction. Int Heart J 55: 101-105, 2014.
133. Tanaka M, Nakae S, Terry RD, Mokhtari GK, Gunawan F, Balsam LB, Kaneda H, Kofidis T, Tsao PS, and Robbins RC. Cardiomyocyte-specific Bcl-2 overexpression attenuates ischemia-reperfusion injury, immune response during acute rejection, and graft coronary artery disease. Blood 104: 3789-3796, 2004.
134. Tattoli I, Travassos LH, Carneiro LA, Magalhaes JG, and Girardin SE. The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation. Semin Immunopathol 29: 289-301, 2007.
135. Toldo S, Das A, Mezzaroma E, Chau VQ, Marchetti C, Durrant D, Samidurai A, Van Tassell BW, Yin C, Ockaili RA, Vigneshwar N, Mukhopadhyay ND, Kukreja RC, Abbate A, and Salloum FN. Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice. Circ Cardiovasc Genet 7: 311-320, 2014.
136. Toldo S, Kannan H, Bussani R, Anzini M, Sonnino C, Sinagra G, Merlo M, Mezzaroma E, De-Giorgio F, Silvestri F, Van Tassell BW, Baldi A, and Abbate A. Formation of the inflammasome in acute myocarditis. Int J Cardiol 171: e119-e121, 2014.
137. Toldo S, Mezzaroma E, and Abbate A. Interleukin-1 blockade in acute myocardial infarction and heart failure: ready for clinical translation? Transl Med 3:e114, 2012.
138. Toldo S, Mezzaroma E, O'Brien L, Marchetti C, Seropian IM, Voelkel NF, Van Tassell BW, Dinarello CA, and Abbate A. Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol 306: H1025-H1031, 2014.
139. Toldo S, Mezzaroma E, Van Tassell BW, Farkas D, Marchetti C, Voelkel NF, and Abbate A. Interleukin-1b blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp Physiol 98: 734-745, 2013.
140. Toldo S, Schatz AM, Mezzaroma E, Chawla R, Stallard TW, Stallard WC, Jahangiri A, Van Tassell BW, and Abbate A. Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse. Cardiovasc Drugs Ther 26: 273-276, 2012.
141. Toldo S, Seropian IM, Mezzaroma E, Van Tassell BW, Salloum FN, Lewis EC, Voelkel N, Dinarello CA, and Abbate A. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 51: 244-251, 2011.
142. Toldo S, Zhong H, Mezzaroma E, Van Tassell BW, Kannan H, Zeng D, Belardinelli L, Voelkel NF, and Abbate A. GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther 343: 587-595, 2012.
143. Topkara VK and Mann DL. Role of microRNAs in cardiac remodeling and heart failure. Cardiovasc Drugs Ther 25: 171-182, 2011.
144. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, and Billiar TR. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201: 1135-1143, 2005.
145. Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, and Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 113: 321-327, 2014.
146. Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, Shah K, Canada J, Voelkel NF, Dinarello CA, and Abbate A. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One 7: e33438, 2012.
147. Van Tassell BW, Seropian IM, Toldo S, Mezzaroma E, and Abbate A. Interleukin-1b induces a reversible cardiomyopathy in the mouse. Inflamm Res 62: 637-640, 2013.
148. Van Tassell BW, Seropian IM, Toldo S, Salloum FN, Smithson L, Varma A, Hoke NN, Gelwix C, Chau V, and Abbate A. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. J Cardiovasc Pharmacol 55: 385-390, 2010.
149. Van Tassell BW, Toldo S, Mezzaroma E, and Abbate A. Targeting interleukin-1 in heart disease. Circulation 128: 1910-1923, 2013.
150. Van Tassell BW, Varma A, Salloum FN, Das A, Seropian IM, Toldo S, Smithson L, Hoke NN, Chau VQ, Robati R, and Abbate A. Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. J Cardiovasc Pharmacol 55: 117-122, 2010.
151. Venkatachalam K, Prabhu SD, Reddy VS, Boylston WH, Valente AJ, and Chandrasekar B. Neutralization of interleukin-18 ameliorates ischemia/reperfusion-induced myocardial injury. J Biol Chem 284: 7853-7865, 2009.
152. Verhoef PA, Kertesy SB, Estacion M, Schilling WP, and Dubyak GR. Maitotoxin induces biphasic interleukin- 1beta secretion and membrane blebbing in murine macrophages. Mol Pharmacol 66: 909-920, 2004.
153. Verhoef PA, Kertesy SB, Lundberg K, Kahlenberg JM, and Dubyak GR. Inhibitory effects of chloride on the activation of caspase-1, IL-1beta secretion, and cytolysis by the P2X7 receptor. J Immunol 175: 7623-7634, 2005.
154. Viles-Gonzalez JF, Fuster V, and Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 25: 1197-1207, 2004.
155. Wang M, Tan J, Wang Y, Meldrum KK, Dinarello CA, and Meldrum DR. IL-18 binding protein-expressing mesenchymal stem cells improve myocardial protection after ischemia or infarction. Proc Natl Acad Sci U S A 106: 17499-17504, 2009.
156. Willerson JT and Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 109: II2-II10, 2004.
157. Woldbaek PR, Sande JB, Strømme TA, Lunde PK, Djurovic S, Lyberg T, Christensen G, and Tønnessen T. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol 289: H708-H714, 2005.
158. Woldbaek PR, Tønnessen T, Henriksen UL, Florholmen G, Lunde PK, Lyberg T, and Christensen G. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc Res 59: 122-131, 2003.
159. Wu H, Ma J, Wang P, Corpuz TM, Panchapakesan U, Wyburn KR, and Chadban SJ. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 21: 1878-1890, 2010.
160. Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, Yamamoto T, Takeshima A, Shinmura K, Shen W, Fukuda K, and Sano M. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J Mol Cell Cardiol 62: 24-35, 2013.
161. Yin Y, Yan Y, Jiang X, Mai J, Chen NC, Wang H, and Yang XF. Inflammasomes are differentially expressed in cardiovascular and other tissues. Int J Immunopathol Pharmacol 22: 311-322, 2009.
162. Zedler S and Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care 12: 595-601, 2006.
163. Zheng F, Xing S, Gong Z, and Xing Q. NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis. Heart Lung Circ 22: 746-750, 2013.
164. Zhu J, Zhang J, Xiang D, Zhang Z, Zhang L, and Wu M. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol 643: 247-253, 2010.
165. Zhu J, Zhang J, Zhang L, Du R, Xiang D, Wu M, Zhang R, and Han W. Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity. Biomed Pharmacother 65: 481-485, 2011.